Analysis

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Investment Insights

12/15/2024

NewAmsterdam Pharma Company N.V. Faces Capital Efficiency Challenges

11/25/2024

News

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a virtual fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET.

03/31/2025

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to file for European approval in 2025, with ongoing trials potentially confirming additional cardiovascular benefits. Despite competition, obicetrapib's oral administration and lack of side effects position it favorably against injectable PCSK9 inhibitors.

02/28/2025

Profitability

Gross Profit Margin	99.96 %
Net Income Per EBT	100 %
Net Profit Margin	-512.33 %
Return on Assets	-26.85 %
Return on Equity	-50.12 %

Dividends

Dividend Yield (FWD)	Nil
Dividend Per Share	Nil
Payout Ratio	Nil
Payout Date	Nil
Ex-Dividend Date	Nil
Latest Announced Dividend	Nil

Income Statement

Revenue	$0.05B
Gross Profit	$0.05B
Gross Profit Ratio	100%
EBITDA	$-0.24B
Net Income	$-0.24B
EPS Diluted	-2.56

Balance Sheet

Long Term Debt	$0B
Total Liabilities	$0.11B
Total Equity	$0.76B
Total Investments	$0.06B
Total Debt	$0B
Total Assets	$0.86B

Cash Flow Statement

Net Income	$-0.24B
Inventory	$0B
Dividends Paid	$0B
Operating Cash Flow	$-0.16B
Capital Expenditure	$-0B

Symbol Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) a buy, sell, or hold?

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) can sell. Click on Rating Page for detail.

What is NewAmsterdam Pharma Company N.V. Ordinary Shares's stock price?

The price of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is 18 and it was updated on 2025-04-04 01:27:37.

Is NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) overvalued or undervalued?

Currently NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is in undervalued.

News

From:

To:

Show entries

Search:

News
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution NewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures, obicetrapib's clean safety profile and efficacy position it well in the cardiovascular market. The PREVAIL trial is crucial for proving obicetrapib's ability to reduce major cardiovascular events, a key to regulatory approval and market adoption. Fri, Feb. 28, 2025
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update -- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- Wed, Feb. 26, 2025
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: Tue, Feb. 25, 2025
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 138,000 of NewAmsterdam's ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). Fri, Feb. 07, 2025
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 58,000 of NewAmsterdam's ordinary shares to two non-executive new hires and a grant of inducement share options covering 170,800 of NewAmsterdam's ordinary shares to Maryellen McQuade, the Company's new Chief People Officer. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). Thu, Jan. 09, 2025

Showing 1 to 5 of 5 entries

Previous1Next

SEC Filings

Show entries

Search:

SEC Filings
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 4 SEC Filings 03/28/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 4 SEC Filings 03/26/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 4 SEC Filings 03/19/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - EFFECT SEC Filings 03/11/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 424B3 SEC Filings 03/10/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 4 SEC Filings 03/06/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 4 SEC Filings 03/05/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - S-3 SEC Filings 02/28/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 8-K - Current report SEC Filings 02/26/2025
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - 10-K - Current report SEC Filings 02/26/2025

Showing 1 to 10 of 199 entries

Previous1 2 3 4 5…20Next

Press Releases

Show entries

Search:

StockPrice Release
Newamsterdam pharma to present at the 24th annual needham virtual healthcare conference 03/31/2025
Newamsterdam pharma reports full year 2024 financial results and provides corporate update 02/26/2025
Newamsterdam pharma to participate at upcoming investor conferences in march 02/25/2025
Newamsterdam pharma reports inducement grants under nasdaq listing rule 5635(c)(4) 02/07/2025
Newamsterdam pharma reports inducement grants under nasdaq listing rule 5635(c)(4) 01/09/2025
Newamsterdam pharma announces closing of upsized $479.0 million public offering of ordinary shares and pre-funded warrants, including full exercise of the underwriters' option to purchase additional shares 12/13/2024
Newamsterdam pharma announces pricing of upsized $416.5 million public offering of ordinary shares and pre-funded warrants 12/11/2024
Newamsterdam pharma announces commencement of $300 million public offering of ordinary shares and pre-funded warrants 12/10/2024
Newamsterdam pharma announces positive topline data from pivotal phase 3 broadway clinical trial evaluating obicetrapib in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia 12/10/2024
Newamsterdam pharma reports inducement grants under nasdaq listing rule 5635(c)(4) 12/06/2024

Showing 1 to 10 of 52 entries

Previous1 2 3 4 5 6Next

More Headlines

Show entries

Search:

News
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritten public offering of (i) 14,667,347 of the Company's ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share, which includes the exercise in full of the underwriters' option to purchase an additional 2,550,000 Ordinary Shares, and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (such offering, the “Offering”). All of the securities sold in the Offering were sold by the Company. 12/13/2024
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of (i) 12,117,347 of the Company's ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants,” such offering, the “Offering”). The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $416.5 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 Ordinary Shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on or about December 13, 2024, subject to satisfaction of customary closing conditions. 12/11/2024
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts NewAmsterdam Pharma Company N.V.'s drug obicetrapib achieved positive results in phase 3 BROADWAY study, significantly reducing LDL-C in ASCVD and HeFH patients when added to statins. Positive data enables potential FDA regulatory application in 2025, with further data releases and peer-reviewed publications as upcoming catalysts. The seven major atherosclerotic cardiovascular disease markets is expected to reach $29.7 billion by 2034. 12/11/2024
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of $300.0 million of the Company's ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” and such offering, the “Offering”). All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of Ordinary Shares, less underwriting discounts and commissions. The proposed Offering is subject to market and other conditions and there can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or terms of the proposed Offering. 12/10/2024
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? On Tuesday, NewAmsterdam Pharma Company N.V. NAMS revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. 12/10/2024
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia -- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p 12/10/2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, The Netherlands and MIAMI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 79,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees'acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). 12/06/2024
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study NewAmsterdam Pharma crashed Wednesday after the company said its experimental cholesterol treatment lowered "bad" LDL by roughly 50% The post NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study appeared first on Investor's Business Daily. 11/20/2024
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 – Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% – – Safety results comparable to placebo – NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (“HeFH”), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. 11/18/2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 97,600 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). 11/01/2024

Showing 1 to 10 of 48 entries

Previous1 2 3 4 5Next

Unlock

NAMS Ratings Summary

Quant

Sell

NAMS Quant Ranking

Sector	Healthcare
Industry	Biotechnology
Quant Rating	Sell
Quant Score	2

Is NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) a buy, sell, or hold?

What is NewAmsterdam Pharma Company N.V. Ordinary Shares's stock price?

Is NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) overvalued or undervalued?

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt